ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Changes in nationwide thyroid hormone replacement use during the pandemic: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) Study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The COVID-19 pandemic and associated measures have had significant impacts on healthcare services, including medication use. We aimed to investigate the nationwide changes in thyroid hormone preparation (THP) utilization before, during, and after the COVID-19 restrictions. We obtained nationwide outpatient THP sales and projected prescribing data for the period between 01.03.2018 and 31.12.2022 from IQVIA Turkey. The average monthly THP consumption, cost, and quarterly projected prescribing levels were analyzed across three periods: "before restrictions" (BfR, 01.03.2018-31.03.2020), "during restrictions" (DuR, 01.04.2020-31.03.2022), and "after restrictions" (AfR, 01.04.2022-31.12.2022). Drug consumption levels were calculated using DID (defined daily dose per 1000 inhabitants per day) parameter. Mean monthly consumption of THPs across BfR, DuR, and AfR was 15.8 ± 3.0, 18.2 ± 4.0 (p > 0.05), and 21.1 ± 3.7 DID (p = 0.001 vs. BfR), respectively. Cost of THPs increased from €2.5 m ± 0.4 m in BfR to €2.8 m ± 0.6 m in DuR (p > 0.05), and €3.5 m ± 0.7 m in AfR (p < 0.001 vs. BfR, p = 0.009 vs. DuR). Projected prescribing levels of these drugs declined from 6.9 ± 0.4 DID in BfR to 6.2 ± 0.5 DID in DuR (p = 0.005), then rose to 7.3 ± 0.03 DID in AfR (p = 0.003 vs. DuR). Ongoing THP users accounted for 89.4% of all projected THP prescriptions and followed the overall trend. Projected prescribing for new users remained stable across three periods (p > 0.05). This study demonstrated that THP utilization showed a modest upward trend since the onset of the COVID-19 pandemic. The increase in consumption following the relaxation of restrictions might be associated with a potentially elevated need for pharmacotherapy, likely due to reduced healthcare access during the extraordinary conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.